Head of Early Research and Development @ (April 2025 - July 2026)
Chief Scientific Officer @ (December 2022 - July 2026)
Executive Director, Radioligand Therapy Lead @ (July 2021 - November 2022)
Head, Radioligand Therapy (RLT) Drug Discovery @ (July 2021 - November 2022)
Associate Member, Associate Professor @ (March 2017 - July 2021)
Assistant Member, Assistant Professor @ (June 2012 - September 2017)
Instructor @ (November 2011 - May 2012)
Leopoldina Foundation Postdoctoral Research Fellow @ (July 2009 - October 2011)
Thomas Reiner Education
Technical University of Munich
Doctor of Philosophy - PhD (Chemistry)
2006-2009
Technical University of Munich
Master of Science - MS (Chemistry)
2005-2006
Technical University of Munich
Bachelor of Science - BS (Chemistry)
2001-2005
Thomas Reiner Summary
Thomas Reiner, based in Basel, BS, CH, is currently a Chief Scientific Officer at NUCLIDIUM AG. Thomas Reiner brings experience from previous roles at Lantheus, Evergreen Theragnostics, Novartis Institutes for BioMedical Research (NIBR) and Advanced Accelerator Applications. Thomas Reiner holds a 2006 - 2009 Doctor of Philosophy - PhD in Chemistry @ Technical University of Munich. Thomas Reiner has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Thomas Reiner?
Find contact details for 700 million professionals.